Shanghai No.1 Pharmacy Co.,Ltd. (SHA:600833)
8.98
-0.15 (-1.64%)
Nov 18, 2026, 3:00 PM CST
Shanghai No.1 Pharmacy Revenue
Shanghai No.1 Pharmacy had revenue of 540.23M CNY in the quarter ending September 30, 2026, a decrease of -0.41%. This brings the company's total for the last twelve months to 2.11B, up 1.32% year-over-year. In the year 2025, Shanghai No.1 Pharmacy had annual revenue of 2.13B with 11.23% growth. That makes Shanghai No.1 Pharmacy the 14,179th largest company in the world by revenue and 2,519th in China.
Revenue (ttm)
2.11B
Revenue Growth
+1.32%
P/S Ratio
0.96
Revenue / Employee
2.58M
Employees
818
Market Cap
2.00B
Revenue by Segment
- Pharmaceutical Retail 1.27B 61.2%
- Pharmaceutical Wholesale 802.95M 38.8%
Fiscal year ended Dec 31, 2025 See the full Shanghai No.1 Pharmacy breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.13B | 215.08M | 11.23% |
| Dec 31, 2024 | 1.92B | 95.64M | 5.26% |
| Dec 31, 2023 | 1.82B | -836.39M | -31.49% |
| Dec 31, 2022 | 2.66B | 1.26B | 89.94% |
| Dec 31, 2021 | 1.40B | -188.62M | -11.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| DaShenLin Pharmaceutical Group | 28.74B |
| Yifeng Pharmacy Chain | 25.38B |
| LBX Pharmacy Chain Joint Stock Company | 22.82B |
| Luyan Pharma | 21.57B |
| Cachet Pharmaceutical | 17.25B |
| Yixintang Pharmaceutical Group | 17.03B |
| ShuYu Civilian Pharmacy Corp. | 10.85B |
| Jianzhijia Pharmaceutical Chain Group | 8.65B |